Conditionally MYC: Insights from Novel Transgenic Models
Overview
Authors
Affiliations
MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.
MYC inhibitors in multiple myeloma.
Martinez-Martin S, Soucek L Cancer Drug Resist. 2022; 4(4):842-865.
PMID: 35582389 PMC: 8992455. DOI: 10.20517/cdr.2021.55.
An "-omycs" Toolbox to Work with MYC.
Whitfield J, Soucek L Methods Mol Biol. 2021; 2318:1-11.
PMID: 34019283 DOI: 10.1007/978-1-0716-1476-1_1.
The potential of multi-compound nanoparticles to bypass drug resistance in cancer.
Da Silva C, Peters G, Ossendorp F, Cruz L Cancer Chemother Pharmacol. 2017; 80(5):881-894.
PMID: 28887666 PMC: 5676819. DOI: 10.1007/s00280-017-3427-1.
STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
Bryson B, Junk D, Cipriano R, Jackson M Cell Cycle. 2016; 16(4):319-334.
PMID: 27892764 PMC: 5324753. DOI: 10.1080/15384101.2016.1259037.
Khaleghian M, Jahanzad I, Shakoori A, Emami Razavi A, Azimi C Iran Red Crescent Med J. 2016; 18(2):e21221.
PMID: 27175302 PMC: 4863201. DOI: 10.5812/ircmj.21221.